Navocaftor is under clinical development by Sionna Therapeutics and currently in Phase II for Cystic Fibrosis.

BIOC-11 is under development for the treatment of bronchiectasis caused by Pseudomonas aeruginosa and cystic fibrosis. This candidate is formulated as an isotonic, buffered aqueous solution for oral ...

INR:5815. sikkim state lottery live draw New drug for cystic fibrosis! Kalydeco approved by the EU for use in infants aged 4-6 months The ranking o ...

This year marked the 22 nd anniversary of Carols by Candlelight, an annual event held in memory of Alice Martineau, a ...

INR:0955. crypto games casino Beijing Nanjiao Cancer Hospital suspended outpatient services due to suspicious nucleic acid test results on garbage truck Big n ...

Revealing the structure of hinge-like protein provides new ideas for treating cystic fibrosis ...

According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.

Krystal Biotech's VYJUVEK, a groundbreaking gene therapy for DEB, achieved $83.8M in Q3 2024 sales. Read why I rate KRYS ...

Researchers at National Jewish Health and colleagues have completed the first study comparing lung macrophages in multiple ...

In STAT's "jealousy list" for 2024, STAT staffers explain what makes a selection of stories they read in other publications ...

A $42,000 grant from NASA and INBRE will further CF research, through a collaborative effort spanning to India and the United Kingdom.

The Food and Drug Administration (FDA) has approved Alyftrek ™ (vanzacaftor/tezacaftor/deutivacaftor) for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one ...